Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension

NCT04753840 | Recruiting

• 1 other identifier: HenanICE202103
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.

Conditions

Hypertension

Outcome Measures

Primary Outcomes (2)

• Mean systolic blood pressure

  24-hour Mean systolic blood pressure measured by Ambulatory blood pressure monitoring

  3 months

• Mean diastolic blood pressure

  24-hour Mean diastolic blood pressure measured by Ambulatory blood pressure monitoring

  3 months

Secondary Outcomes (5)

• Concentration of Renalase

  3 months

• Concentration of catecholamine

  3 months

• Concentration of adenosine

  3 months

• Concentration of bradykinin

  3 months

• Concentration of renin

  3 months

Study Arms (3)

Experimental A: Drug group+lifestyle intervention

EXPERIMENTAL

Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.

Other: Antihypertensive drugs; Behavioral: lifestyle intervention

Experimental B: RIPC group+lifestyle intervention

EXPERIMENTAL

The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.

Other: remote ischemic preconditioning（RIPC）; Behavioral: lifestyle intervention

Experimental c: lifestyle intervention

OTHER

The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.

Behavioral: lifestyle intervention

Interventions

Antihypertensive drugs OTHER

One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic

Experimental A: Drug group+lifestyle intervention

remote ischemic preconditioning（RIPC） OTHER

40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.

Experimental B: RIPC group+lifestyle intervention

lifestyle intervention BEHAVIORAL

Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.

Experimental A: Drug group+lifestyle intervention; Experimental B: RIPC group+lifestyle intervention; Experimental c: lifestyle intervention

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed patients with mild hypertension (SBP: 140\~159mmHg; DBP: 90\~99mmHg)

You may not qualify if:

• Cannot tolerate RIPC
• Non-essential hypertension
• patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance
• patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.

Sponsors & Collaborators

• Henan Institute of Cardiovascular Epidemiology: lead

Study Sites (1)

Fuwai central China Cardiovascular hospital

Zhengzhou, Henan, 450008, China

RECRUITING

Related Publications (2)

• Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens. 2014 Jul;27(7):918-25. doi: 10.1093/ajh/hpu004. Epub 2014 Mar 13.

  PMID: 24627443 BACKGROUND

• Moro L, Pedone C, Mondi A, Nunziata E, Antonelli Incalzi R. Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people. Atherosclerosis. 2011 Dec;219(2):750-2. doi: 10.1016/j.atherosclerosis.2011.08.046. Epub 2011 Sep 7.

  PMID: 21945497 BACKGROUND

MeSH Terms

Conditions

Hypertension

Interventions

Antihypertensive Agents

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Cardiovascular Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses

Study Officials

• Muwei Li, MD

  Chinese Academy of Medical Sciences, Fuwai Hospital

  STUDY CHAIR

Central Study Contacts

En Li

CONTACT

13525070525; 1799077212@qq.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2021
• First Posted: February 15, 2021
• Study Start: July 3, 2021
• Primary Completion: December 1, 2025
• Study Completion (Estimated): December 1, 2030
• Last Updated: September 15, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)